Dry Eye Syndromes Clinical Trial
Official title:
Quantum Molecular Resonance Effects on Patients With Dry Eye Disease
NCT number | NCT05469932 |
Other study ID # | AAA |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | February 14, 2021 |
Est. completion date | December 2022 |
The Rexon Eye device (Resono Ophthalmic Inc, Trieste, Italy) is a new device based on QMR technology. Quantum Molecular Resonance (QMR) is a technique in which low-intensity, high-frequency electric currents are administered to a biological tissue through contact electrodes. The device applies stimulation to the epidermis of closed eyelids up to the lid margin by means of specially designed goggles. Previous studies have shown that it is relatively safe with high patient satisfaction. Preliminary studies have also shown it is effective for accelerating healing in chronic wounds and treating dry eye symptoms.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | December 2022 |
Est. primary completion date | December 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients above the age of 18 years - Patients who are willing and able to consent and adhere to the research plan - Patients diagnosed with dry eye or patients who are at risk for dry eye Exclusion Criteria: - Active infection of the eyelid or periorbital area - Patients who are pregnant or lactating - Patients under the age of 18 - Those scheduled for (<30 days) or immediately after (<30 days) ocular surgery (excluding cataract and eyelid surgery) - Patient who do not adhere to all four treatment sessions. |
Country | Name | City | State |
---|---|---|---|
Israel | Shamir Medical Center | Tel Aviv |
Lead Sponsor | Collaborator |
---|---|
Assaf-Harofeh Medical Center |
Israel,
Ferrari G, Colucci A, Barbariga M, Ruggeri A, Rama P. High Frequency Electrotherapy for the Treatment of Meibomian Gland Dysfunction. Cornea. 2019 Nov;38(11):1424-1429. doi: 10.1097/ICO.0000000000002063. — View Citation
Pedrotti E, Bosello F, Fasolo A, Frigo AC, Marchesoni I, Ruggeri A, Marchini G. Transcutaneous periorbital electrical stimulation in the treatment of dry eye. Br J Ophthalmol. 2017 Jun;101(6):814-819. doi: 10.1136/bjophthalmol-2016-308678. Epub 2016 Sep 22. — View Citation
Sella S, Adami V, Amati E, Bernardi M, Chieregato K, Gatto P, Menarin M, Pozzato A, Pozzato G, Astori G. In-vitro analysis of Quantum Molecular Resonance effects on human mesenchymal stromal cells. PLoS One. 2018 Jan 2;13(1):e0190082. doi: 10.1371/journal.pone.0190082. eCollection 2018. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Ocular Surface Disease Index (OSDI) Questionnaire | A validated questionnaire that assess the symptoms of ocular irritation in dry eye disease. and how they affect functioning related to vision. This 12-item questionnaire assesses dry eye symptoms and the effects it has on vision-related function in the past week of the patient's life. The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers. Patients rate their responses on a 0 to 4 scale with 0 corresponding to "none of the time" and 4 corresponding to "all of the time." A final score is calculated which ranges from 0 to 100 with scores 0 to 12 representing normal, 13 to 22 representing mild dry eye disease, 23 to 32 representing moderate dry eye disease, and greater than 33 representing severe dry eye disease | At baseline (pre-intervention) and up to 4 weeks after treatment ends (after-intervention) | |
Secondary | Change in Meibomian gland dysfunction Grading | Min = 0. Max =4. Low score: low Meibomian gland dysfunction (normal) High score: Meibomian gland dysfunction (pathology) | At baseline (pre-intervention) and up to 4 weeks after treatment ends (after-intervention) | |
Secondary | Change in Corneal Staining | We measure the amount of fluorescein dots (score 0 for 0 dots, score 1 for 1-5 dots, score 2 for 6-30 dots, score 3 for >30 dots) Additional 1 point for - Patches of confluent staining Additional 1 point for - Staining in the pupillary area Additional 1 point for - One or more filament Min = 0. Max =6. Low score: Clear cornea (normal) High score: pathological cornea (pathology) |
At baseline (pre-intervention) and up to 4 weeks after treatment ends (after-intervention) | |
Secondary | Change in Tear breakup time | Measures the number of seconds for the fluorescein to break and thus assesses the stability of tear film. Min = 0. Max = 20. Low score: Tear film instability (pathology) High score: Normal Tear film stability (normal) |
At baseline (pre-intervention) and up to 4 weeks after treatment ends (after-intervention) | |
Secondary | Change in Schirmer with anesthesia | The Schirmer's test evaluates aqueous tear production. It is helpful in the assessment of patients with signs and/or symptoms of dry eye - as it can determine whether surface dryness is due to reduced tear production from the lacrimal glands as opposed to some other cause. The Schirmer basal secretion test was performed for each patient in both eyes in the following manner: Topical anesthetic was applied to the eye, and the conjunctival fornix was dried with a cotton tip applicator. After a 2-minute waiting period, the paper strip was folded and placed between the lower eyelid and the globe at the junction between the middle and lateral thirds of the eyelid. After 5 minutes, the filter paper is removed and the amount of wetting from the fold is measured (mm) We used the standard (no. 41 Whatman) filter paper. Min = 0 mm Max = 30 mm Low score: Low tear secretion (pathology) High score: Normal tear secretion (normal) |
At baseline (pre-intervention) and up to 4 weeks after treatment ends (after-intervention) | |
Secondary | Change in Corrected visual acuity | LogMAR scale. Min = 0. Max = 1. Low score: Normal visual acuity (normal) High score: Imparied visual acuity (pathology) |
At baseline (pre-intervention) and up to 4 weeks after treatment ends (after-intervention) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
Not yet recruiting |
NCT06379685 -
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
|
Phase 1 | |
Recruiting |
NCT04701086 -
3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis
|
N/A | |
Active, not recruiting |
NCT03697876 -
Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel
|
Phase 1 | |
Terminated |
NCT02815293 -
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
|
Phase 3 | |
Completed |
NCT02910713 -
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
|
N/A | |
Completed |
NCT04104997 -
A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers
|
Phase 1 | |
Recruiting |
NCT02595606 -
0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients
|
Phase 4 | |
Completed |
NCT01711424 -
An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease
|
N/A | |
Completed |
NCT01202747 -
Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction
|
Phase 2/Phase 3 | |
Completed |
NCT01015209 -
Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers
|
Phase 1 | |
Completed |
NCT00969280 -
Acupuncture for Dry Eye Syndrome
|
Phase 3 | |
Completed |
NCT01496482 -
Comparison of Evaporimetry With the Established Methods of Tear Film Measurement
|
N/A | |
Completed |
NCT00739713 -
Effects of Sea Buckthorn Oil on Dry Eye
|
N/A | |
Completed |
NCT00756678 -
Efficacy and Acceptability of Two Lubricant Eye Drops
|
Phase 4 | |
Completed |
NCT00370747 -
Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome
|
Phase 2 | |
Completed |
NCT00349440 -
Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy
|
Phase 4 | |
Completed |
NCT05162261 -
to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction
|
N/A | |
Completed |
NCT02871440 -
A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye
|
Phase 3 | |
Completed |
NCT05042960 -
Computer Screen Properties Study
|
N/A |